Cell and Gene Therapy Market is expected to reach a revenue of USD 111.4 Bn by 2033, at 19.3% CAGR: Dimension Market Research

New York, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Overview

According to Dimension Market Research, the Cell and Gene Therapy Market size is expected to reach USD 22.8 billion by 2024 and is further anticipated to reach USD 111.4 billion by 2033. The market is anticipated to register a CAGR of 19.3% from 2024 to 2033.

Cell & gene therapy provides solutions related to genes and cells, as it deals with research & development, testing, production, and distribution of products and treatment procedures related to genes and cells. Hospitals, research laboratories, pharmaceutical companies, pharmacies, research institutions, and universities are included in delivering the applications associated with gene & cell therapies.

The US Overview

The Cell and Gene Therapy Market in the US is projected to reach USD 10.2 billion in 2024 at a compound annual growth rate of 18.1% over its forecast period.

The U.S. cell and gene therapy market benefits from strong research infrastructure, various clinical trials, and FDA support, driving innovation and growth. Investments, partnerships, and developments in manufacturing expand opportunities, driven by the growing demand for personalized cancer and genetic disorder therapies. However, high costs and manufacturing challenges limit access, highlighting the need for affordable solutions to unlock the market’s potential.

Click to Request Sample Report and Drive Impactful Decisions: https://dimensionmarketresearch.com/report/cell-and-gene-therapy-market/request-sample/

Important Insights

• The Cell and Gene Therapy Market is expected to grow by USD 111.4 billion by 2033 from 2025 with a CAGR of 19.3%.
• The Cell Therapy segment is expected to get the largest share of the Cell and Gene Therapy Market in 2024.
• The Oncological disorders as an indication segment is expected to be leading the market in 2024.
• The hospital segment is expected to get the largest revenue share in 2024 in the Cell and Gene Therapy Market.
• North America is predicted to have a 51.1% share of revenue share in the Global Cell and Gene Therapy in 2024.

Global Cell and Gene Therapy Market: Trends

• Rise of Allogeneic Therapies: There’s a major focus on developing off-the-shelf, allogeneic cell therapies, which are more scalable & accessible than autologous approaches.
• Integration of Artificial Intelligence: AI & machine learning are being used to streamline research processes, optimize clinical trial designs, and improve patient stratification.
• Focus on Combination Therapies: Integrating gene therapies with existing treatments, like immunotherapy, is gaining traction to enhance efficacy and patient outcomes.
• Emphasis on Regulatory Pathway Optimization: Companies are actively engaging with regulatory bodies early in the development process to look into complex approvals and expedite market entry.

Cell and Gene Therapy Market: Competitive Landscape

The cell and gene therapy market is transforming rapidly, driven by established pharmaceutical firms and biotech startups. Companies aim for innovation through R&D, strategic collaborations, and expanding treatment pipelines for cancer, genetic, and rare diseases. Key competitive factors like clinical trial success, regulatory approvals, and manufacturing capabilities. Further, partnerships with academic institutions and expansion into emerging markets enhance their competitive edge.

Some of the major players in the market include Amgen, Novartis, Pfizer, Biogen, and more.

Some of the prominent market players:

• Amgen
• Novartis
• Pfizer
• Biogen
• Bristol-Myers Squibb Company
• Thermo Fisher Scientific
• Kolon TissueGene Inc
• JCR Pharmaceuticals
• Alnylam Pharmaceuticals
• Sanofi
• Other Key Players

Transform your business approach with strategic insights from our report. Get in touch to request our brochure today at https://dimensionmarketresearch.com/report/cell-and-gene-therapy-market/download-reports-excerpt/

Cell and Gene Therapy Market Scope

Segment Analysis

The global cell and gene therapy market is segmented by indications, including genetic, cardiovascular, neurological, and oncological disorders. Among these, oncological disorders are anticipated to dominate market revenue in 2024, driven by significant R&D efforts targeting cancer at the genetic level, allowing more personalized treatments.

The genetic disorder segment is anticipated to grow the fastest, driven by rising genetic and chronic disease prevalence and government initiatives promoting genetic testing. Further, developments in cardiovascular research expand the market by improving diagnostics and treatment, accelerating the adoption of innovative therapies for genetic and hereditary conditions.

Cell and Gene Therapy Market Segmentation

By Therapy Type

• Cell Therapy
  • Stem Cells
  • T Cells
  • Dendritic Cells
  • NK Cells
  • Tumor Cells
• Gene Therapy

 By Indication

• Genetic Disorders
• Cardiovascular Disorders
• Neurological Disorders
• Oncological Disorders
• Others

By Delivery Method

• In Vivo
• Ex Vivo

By End User

• Hospitals
• Academic & Research Centers
• Cancer Care Centers
• Others

Purchase the Competition Analysis Dashboard Today at https://dimensionmarketresearch.com/checkout/cell-and-gene-therapy-market/

Global Cell and Gene Therapy Market: Driver

• Rising Demand for Personalized Medicine: The major focus on customized therapies, mainly for cancer & genetic disorders, is driving market growth.
• Advancements in R&D and Clinical Trials: Ongoing innovations and various trials accelerate new treatment development.
• Favorable Regulatory Support: Regulatory bodies like the FDA offer simplified processes, encouraging innovation and approvals.
• Strategic Partnerships and Investments: Collaborations between pharma, biotech firms, and academic institutions boost research, manufacturing, and market expansion.

Global Cell and Gene Therapy Market: Restraints

• High Development and Treatment Costs: Expensive R&D and therapy costs limit patient access & insurance coverage.
• Manufacturing Challenges: Complex production processes impact the scalability and timely delivery.
• Regulatory and Compliance Hurdles: Navigating strict regulations can delay approvals & market entry.
• Limited Patient Access and Infrastructure: Inadequate healthcare infrastructure in certain regions restricts the availability of advanced therapies.

Global Cell and Gene Therapy Market: Opportunities

• Expansion into Emerging Markets: The rise in healthcare infrastructure in developing regions provides new market opportunities.
• Innovations in Delivery Systems: Development in gene-editing tools and delivery technologies improves treatment efficiency.
• Increased Government and Private Funding: Growing investments boost R&D, clinical trials, and manufacturing capabilities.
• Collaborations with Academic Institutions: Partnerships provide access to advanced research and accelerate product development.

Click to Request Sample Report and Drive Impactful Decisions at https://dimensionmarketresearch.com/report/cell-and-gene-therapy-market/request-sample/

Regional Analysis

North America is set to get 51.1% of the cell and gene therapy market revenue in 2024, driven by a strong healthcare infrastructure, over 400 active companies, and many clinical trials. The U.S. plays a major role, with the FDA’s collaborative regulatory approach fostering innovation.

Further, Europe’s growth is assisted by the Horizon 2021 program, promoting gene therapy utilizing viral vectors. The region benefits from strong infrastructure, a skilled workforce, and new research initiatives, enhancing manufacturing capabilities and competitiveness, and positioning Europe for significant advancements in the global cell and gene therapy market.

By Region

North America

• The U.S.
• Canada

Europe

• Germany
• The U.K.
• France
• Italy
• Russia
• Spain
• Benelux
• Nordic
• Rest of Europe

Asia-Pacific

• China
• Japan
• South Korea
• India
• ANZ
• ASEAN
• Rest of Asia-Pacific

Latin America

• Brazil
• Mexico
• Argentina
• Colombia
• Rest of Latin America

Middle East & Africa

• Saudi Arabia
• UAE
• South Africa
• Israel
• Egypt
• Rest of MEA

Recent Developments in the Cell and Gene Therapy Market

• April 2024: The President of India launched India’s first home-grown gene therapy for cancer at IIT Bombay, which is a breakthrough in the battle against cancer. As this line of treatment, named “CAR-T cell therapy," is available and less expensive, it provides new hope for the whole of humankind.
• February 2024: BioNTech SE along with Autolus Therapeutics plc unveiled a strategic collaboration aimed at developing both companies’ autologous CAR-T programs towards commercialization, pending regulatory authorizations.
• January 2024: AbbVie and Umoja Biopharma introduced two exclusive options and license agreements to create multiple in-situ generated CAR-T cell therapy candidates in oncology using Umoja's proprietary VivoVecTM platform, as the first agreement delivering AbbVie an exclusive option to license Umoja's CD19 directed in-situ generated CAR-T cell therapy.
• December 2023: The US FDA approved two major treatments, Casgevy and Lyfgenia, highlighting the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older.
• November 2023: AstraZeneca announced a collaboration & investment agreement with Cellectis, a clinical-stage biotechnology company, to accelerate the development of next-generation therapeutics in areas of high unmet need, like immunology, oncology, and rare diseases.

Browse More Related Reports

TheKingdom of Saudi Arabia (KSA)'s Elderly Healthcare Market size is expected to reach a value of USD 1,012.6 million in 2024, and it is further anticipated to reach a market value of USD 4,542.4 million by 2033 at a CAGR of 18.1%.

Global Wellness Tourism Market is forecasted to reach USD 1,094.9 billion by the end of 2024 and grow to USD 3,254.7 billion in 2033, with a CAGR of 12.9%.

Global Gastroenterology Market is forecasted to reach USD 38.5 billion by the end of 2024 and grow to USD 66.4 billion in 2033, with a CAGR of 6.2%.

Global DNA Sequencing Market is forecasted to reach USD 16.0 billion by the end of 2024 and grow to USD 97.8 billion in 2033, with a CAGR of 22.3%.

The Global Antidepressant Drugs Market is projected to reach USD 20.1 billion in 2024 and grow at a compound annual growth rate of 3.3% from there until 2033 to reach a value of USD 26.9 billion.

The Global 3D Printing in Healthcare Market is projected to reach USD 10.7 billion in 2024 and grow at a compound annual growth rate of 19.2% from there until 2033 to reach a value of USD 51.7 billion.

The Global Chronic Disease Management Market is projected to reach USD 5.7 billion in 2024 and grow at a compound annual growth rate of 13.9% from there until 2033 to reach a value of USD 18.4 billion.

The Global Post Anaesthesia Care Unit Device (PACU) Market is projected to reach USD 13.7 billion in 2024 and grow at a compound annual growth rate of 8.1% from there until 2033 to reach a value of USD 27.5 billion.

The Global Postoperative Management Market is projected to reach USD 42.5 billion in 2024 and grow at a compound annual growth rate of 5.4% from there until 2033 to reach a value of USD 68.3 billion.

The Global Senolytic Drugs Market is projected to reach USD 42.5 million in 2024 and grow at a compound annual growth rate of 35.8% from there until 2033 to reach a value of USD 667.6 million.

About Dimension Market Research (DMR):

Dimension Market Research (DMR) is a market research and consulting firm based in India & US, with its headquarters located in the USA (New York). The company believes in providing the best and most valuable data to its customers using the best resources analysts into work, to create unmatchable insights into the industries, and markets while offering in-depth results of over 30 industries, and all major regions across the world. We also believe that our clients don’t always want what they see, so we provide customized reports as well, as per their specific requirements to create the best possible outcomes for them and enhance their business through our data and insights in every possible way.